The objective of the Clinical Trials Laboratory Core (CTLC) is to facilitate high quality translational research at the H. Lee Moffitt Cancer Center and Research Institute. The CTLC is designed to provide a combined resource for the Basic Science and Clinical Investigations programs. This CTLC has the ability to measure pharmacokinetic drug levels of novel chemotherapeutic agents and to measure and target molecular endpoints. The CTLC also provides a means of collection and simple sample processing of many liquid samples utilized for pharmacokinetic measurement. The CTLC is composed of three separate, but related laboratories. Chromatography and Mass Spectrometry drive the Clinical Pharmacology Lab (CPL) where pharmacokinetic analysis takes place. The Translational Research Lab (TRL) provides assays such as Apoptosis measurements, Western Blot analysis, Electrophoretic Mobile Shift Assays (EMSA) and Ribonuclease Protection Assay (RPA) for molecular endpoint analysis. The Clinical Research Unit Laboratory (CRU Lab) allows investigators the ability to have their samples obtained and processed in a location within the Clinical Research Unit, the unit of choice here at Moffitt for phase I and II clinical trials involving research sampling. The combination of these laboratories within one core facility helps investigators better perform their research and attain their goals of prevention and cure here at Moffitt. The CTLC goals are to provide efficient and proper collection of biological samples, perform sensitive and specific assays and provide the ability to model the data generated.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Porubsky, Caitlin; Teer, Jamie K; Zhang, Yonghong et al. (2018) Genomic analysis of a case of agminated Spitz nevi and congenital-pattern nevi arising in extensive nevus spilus. J Cutan Pathol 45:180-183
Zhu, Genyuan; Nemoto, Satoshi; Mailloux, Adam W et al. (2018) Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line. Front Immunol 9:1609
Huang, Qingling; Chen, Lihong; Yang, Leixiang et al. (2018) MDMX acidic domain inhibits p53 DNA binding in vivo and regulates tumorigenesis. Proc Natl Acad Sci U S A 115:E3368-E3377
Li, Yafang; Xiao, Xiangjun; Han, Younghun et al. (2018) Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis 39:336-346
Padron, Eric; Ball, Markus C; Teer, Jamie K et al. (2018) Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood 131:2402-2405
Karolak, Aleksandra; Markov, Dmitry A; McCawley, Lisa J et al. (2018) Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues. J R Soc Interface 15:
Liu, Ying; Wang, Hua; Li, Qian et al. (2018) Radiologic Features of Small Pulmonary Nodules and Lung Cancer Risk in the National Lung Screening Trial: A Nested Case-Control Study. Radiology 286:298-306
Correa, John B; Brandon, Karen O; Meltzer, Lauren R et al. (2018) Electronic cigarette use among patients with cancer: Reasons for use, beliefs, and patient-provider communication. Psychooncology 27:1757-1764

Showing the most recent 10 out of 1254 publications